Pfizer
PFE
28.00
+0.50
+1.82%
Pfizer
US · PFE
#133 by market cap
Listed 1970
28.00
+0.50
+1.82%
Live - 5344 symbols - heartbeat 29s ago
· 2026-10-08 08:29
Pre-market
27.95
-0.18%
After-hours
27.98
-0.06%
Overnight
28.00
0.00%
- Market cap
- 159.59B
- P/E (TTM)i
- 36.84
- P/Bi
- 1.87
- EPSi
- 1.36
- Div yieldi
- 6.14%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on PFE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.17, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -1.65% YoY
Margins
- Gross margin
- 74.33%
- Operating margin
- 27.82%
- Net margin
- 12.42%
Key ratios & quality
- Enterprise valuei
- 209.96B
- Altman Z-Scorei
- 2.17
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40.83B | 40.91B | 41.65B | 81.29B | 101.18B | 59.55B | 63.63B | 62.58B |
| Gross profit | 31.84B | 32.85B | 33.17B | 50.47B | 66.83B | 34.60B | 45.78B | 46.51B |
| Selling & admin expenses | 12.61B | 12.73B | 11.60B | 12.70B | 13.68B | 14.77B | 14.73B | 13.79B |
| Research & development | 7.76B | 8.39B | 8.71B | 10.36B | 11.43B | 10.68B | 10.82B | 10.44B |
| Operating profit | 6.73B | 7.31B | 9.51B | 23.70B | 38.12B | 4.42B | 14.94B | 17.41B |
| Pretax profit | 3.59B | 11.32B | 7.04B | 24.31B | 34.73B | 1.06B | 8.02B | 7.52B |
| Tax | -266.00M | 583.00M | 370.00M | 1.85B | 3.33B | -1.12B | -28.00M | -266.00M |
| Net profit | 11.19B | 16.06B | 9.20B | 22.03B | 31.41B | 2.16B | 8.06B | 7.81B |
| Basic EPS | 2 | 3 | 2 | 4 | 6 | 0 | 1 | 1 |
| Diluted EPS | 1.87 | 2.82 | 1.63 | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 13.72B | 14.65B | 16.65B | 17.56B | 14.45B | 15.03B |
| Gross profit | 10.87B | 10.88B | 12.48B | 12.29B | 10.90B | 10.94B |
| Selling & admin expenses | 3.03B | 3.42B | 3.19B | 4.16B | 2.96B | 3.41B |
| Research & development | 2.20B | 2.48B | 2.55B | 3.21B | 2.49B | 2.81B |
| Operating profit | 4.43B | 3.77B | 5.53B | 3.69B | 4.27B | 3.54B |
| Pretax profit | 2.79B | 3.04B | 3.33B | -1.64B | 3.17B | -653.00M |
| Tax | -189.00M | 141.00M | -216.00M | -2.00M | 461.00M | -407.00M |
| Net profit | 2.97B | 2.93B | 3.55B | -1.64B | 2.70B | -237.00M |
| Basic EPS | 1 | 1 | 1 | 0 | 0 | 0 |
| Diluted EPS | 0.52 | 0.51 | 0.62 | -0.29 | 0.47 | -0.04 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 49.93B | 32.80B | 35.07B | 59.69B | 51.26B | 43.33B | 50.36B | 42.90B |
| Cash & ST investments | 18.83B | 9.65B | 12.22B | 31.07B | 22.73B | 12.69B | 20.48B | 13.60B |
| Inventory | 7.51B | 7.07B | 8.02B | 9.06B | 8.98B | 10.19B | 10.85B | 10.65B |
| Total assets | 159.42B | 167.59B | 154.23B | 181.48B | 197.21B | 226.50B | 213.40B | 208.16B |
| Total current liabilities | 31.86B | 37.30B | 25.92B | 42.67B | 42.14B | 47.79B | 43.00B | 36.98B |
| Short-term debt | 8.84B | 16.19B | 2.70B | 2.24B | 2.93B | 10.35B | 6.95B | 3.15B |
| Long-term debt | 32.43B | 34.65B | 35.57B | 34.76B | 31.93B | 60.50B | 56.70B | 60.81B |
| Total liabilities | 95,664,000,000.00 | 104,147,000,000.00 | 90,756,000,000.00 | 104,014,000,000.00 | 101,289,000,000.00 | 137,213,000,000.00 | 124,899,000,000.00 | 121,385,000,000.00 |
| Total equity | 63.76B | 63.45B | 63.47B | 77.46B | 95.92B | 89.29B | 88.50B | 86.78B |
| Retained earnings | 89.55B | 97.67B | 90.39B | 103.39B | 125.66B | 118.35B | 116.73B | 114.61B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 45.86B | 43.70B | 46.92B | 42.90B | 42.82B | 41.36B |
| Cash & ST investments | 17.32B | 13.25B | 14.98B | 13.60B | 13.08B | 11.70B |
| Inventory | 10.85B | 11.67B | 11.47B | 10.65B | 10.67B | 9.95B |
| Total assets | 208.03B | 206.10B | 208.73B | 208.16B | 207.62B | 201.13B |
| Total current liabilities | 36.45B | 37.73B | 36.60B | 36.98B | 34.35B | 32.65B |
| Short-term debt | 4.47B | 4.30B | 4.30B | 3.15B | 3.89B | 2.70B |
| Long-term debt | 56.82B | 56.63B | 56.55B | 60.81B | 59.84B | 60.50B |
| Total liabilities | 117,391,000,000.00 | 117,083,000,000.00 | 115,635,000,000.00 | 121,385,000,000.00 | 117,214,000,000.00 | 115,639,000,000.00 |
| Total equity | 90.64B | 89.01B | 93.10B | 86.78B | 90.40B | 85.49B |
| Retained earnings | 119.59B | 117.61B | 121.15B | 114.61B | 117.24B | 112.09B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 15.83B | 12.59B | 14.40B | 32.58B | 29.27B | 8.70B | 12.74B | 11.70B |
| Depreciation & amortization | 6.15B | 5.76B | 4.68B | 5.19B | 5.06B | 6.29B | 7.01B | 6.59B |
| Free cash flow | 13.69B | 10.54B | 12.18B | 29.87B | 26.03B | 4.79B | 9.84B | 9.08B |
| Dividends paid | -7.98B | -8.04B | -8.44B | -8.73B | -8.98B | -9.25B | -9.51B | -9.77B |
| Stock buybacks / issuance | -12.20B | -8.87B | 0 | 0 | -2.00B | 0 | 0 | -- |
| Ending cash balance | 1.23B | 1.35B | 1.83B | 1.98B | 468.00M | 2.92B | 1.11B | 1.20B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.34B | -582.00M | 4.60B | 5.35B | 2.62B | 835.00M |
| Depreciation & amortization | 1.62B | 1.63B | 1.66B | 1.69B | 1.61B | 1.62B |
| Free cash flow | 1.77B | -1.20B | 4.00B | 4.50B | 2.18B | 302.00M |
| Dividends paid | -2.44B | -2.45B | -2.44B | -2.45B | -2.45B | -2.45B |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.48B | 1.69B | 1.39B | 1.20B | 1.76B | 1.03B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 16.56 | 25.72 | 15.22 | 31.30 | 36.30 | 2.29 | 9.06 | 8.90 |
| ROA %i | 6.73 | 9.96 | 5.98 | 13.09 | 16.57 | 1.00 | 3.65 | 3.69 |
| ROIC %i | 11.05 | 16.02 | 10.12 | 21.45 | 26.37 | 1.76 | 6.37 | 6.16 |
| 5-year avg ROE %i | 16.67 | 19.26 | 20.12 | 24.05 | 24.80 | 21.94 | 18.69 | 17.57 |
| EBIT margin %i | 24.61 | 37.21 | 21.35 | 31.50 | 35.85 | 5.59 | 17.47 | 16.29 |
| FCF / sales %i | 25.41 | 19.31 | 27.71 | 36.74 | 25.95 | 8.19 | 15.46 | 14.50 |
| Current ratioi | 1.57 | 0.88 | 1.35 | 1.40 | 1.22 | 0.91 | 1.17 | 1.16 |
| Quick ratioi | 0.95 | 0.51 | 0.90 | 1.10 | 0.88 | 0.59 | 0.82 | 0.80 |
| Debt / assetsi | 25.88 | 30.34 | 24.82 | 20.39 | 17.68 | 31.28 | 29.83 | 30.73 |
| LT debt / equityi | 51.16 | 54.89 | 56.25 | 45.02 | 33.37 | 67.97 | 64.29 | 70.32 |
| Interest coveragei | 10.03 | 12.23 | 6.17 | 19.83 | 29.05 | 1.48 | 3.60 | 3.82 |
| Revenue CAGR (3Y) %i | -5.81 | -8.17 | -7.45 | 25.81 | 35.24 | 12.66 | -7.84 | -14.80 |
| Net income CAGR (3Y) %i | 17.02 | 30.48 | -24.53 | 25.37 | 25.09 | -38.61 | -28.51 | -37.20 |
| FCF CAGR (3Y) %i | 1.25 | -9.44 | -5.84 | 29.70 | 35.16 | -26.71 | -30.95 | -29.62 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 8.63 | 12.19 | 10.62 | 8.90 | 8.30 | 4.98 |
| ROA %i | 3.67 | 5.09 | 4.59 | 3.69 | 3.60 | 2.13 |
| ROIC %i | 6.18 | 8.12 | 7.29 | 6.16 | 6.22 | 3.78 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.56 | 20.94 | 18.88 | 16.29 | 16.73 | 10.85 |
| FCF / sales %i | 17.96 | 19.49 | 16.53 | 14.50 | 14.98 | 17.25 |
| Current ratioi | 1.26 | 1.16 | 1.28 | 1.16 | 1.25 | 1.27 |
| Quick ratioi | 0.88 | 0.78 | 0.90 | 0.80 | 0.85 | 0.85 |
| Debt / assetsi | 29.46 | 29.56 | 29.15 | 30.73 | 30.70 | 31.42 |
| LT debt / equityi | 62.90 | 63.85 | 60.93 | 70.32 | 66.41 | 71.01 |
| Interest coveragei | 3.50 | 4.72 | 4.39 | 3.82 | 3.94 | 2.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- BioPharma is the largest reported line at 97.52% of revenue, across 2 reported segments.
- The next-largest line, Other business activities, is a distant second at 2.48% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
BioPharma97.52%
Other business activities2.48%
Quote time 2026-10-08 08:29:45 · For reference only, not investment advice and not tailored to your situation.